Immunotherapy for atherosclerosis: An emerging paradigm

Reviews in Cardiovascular Medicine

Volumn 5, Issue 4, 2004, Pages 194-203

  Shah, Prediman K ^a   Chyu, Kuang Yuh ^a   Nilsson, Jan ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Immunosuppression; Low density lipoprotein, oxidized; Malondialdehyde apolipoprotein B 100 peptide antigens; Phospholipid antigens, oxidized; Tolerization; Vaccination

Indexed keywords

APOLIPOPROTEIN B100; AZATHIOPRINE; CD40 LIGAND MONOCLONAL ANTIBODY; CHOLESTEROL ESTER TRANSFER PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PNEUMOCOCCUS VACCINE; RAPAMYCIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; ANTIGEN BINDING; ATHEROSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR MECHANICS; NONHUMAN; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LIPOPROTEINS, LDL; VACCINES;

EID: 10944267006     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
3. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis. 2002;44:357-368.
4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
5. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247:371-380.
6. Hörkkö S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med. 2000;28:1771-1779.
7. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91:281-291.
8. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226.
9. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002;111:927-930.
10. Krieger M, Stern DM. Series introduction: multiligand receptors and human disease. J Clin Invest. 2001;108:645-647.
11. Takeuchi O, Akira S. Genetic approaches to the study of Toll-like receptor function. Microbes Infect. 2002;4:887-895.
12. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol. 2002;169:10-14.
13. Muzio M, Natoli G, Saccani S, et al. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med. 1998; 187:2097-2101.
14. Walton KA, Cole AL, Yeh M, et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003;23:1197-1203.
15. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
16. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161.
17. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003;278:1561-1568.
18. Michelsen KS, Wong MH, Zhang W, et al. Genetic ablation of MyD88, an adaptor molecule involved in TLR-signaling and innate immunity, reduces atherosclerosis and alters plaque phenotype in Apo E null mice without changing circulating cholesterol levels. Circulation. 2003;108(17 suppl IV).
19. Brown MS, Goldstein JL. Atherosclerosis. Scavenging for receptors. Nature. 1990;343:508-509.
20. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-791.
21. Kume N, Kita T. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol. 2001;12:419-423.
22. Minami M, Kume N, Shimaoka T, et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21:1796-1800.
23. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386:292-296.
24. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
25. Perschinka H, Mayr M, Millonig G, et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1060-1065.
26. Afek A, George J, Gilburd B, et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun. 2000;14:115-121.
27. Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789-799.
28. Lamb DJ, Ferns GA. The magnitude of the immune response to heat shock protein-65 following BCG immunization is associated with the extent of experimental atherosclerosis. Atherosclerosis. 2002;165:231-240.
29. Xu O, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993; 341:255-259.
30. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15:297-322.
31. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
32. Gupta S, Pablo AM, Jiang X, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752-2761.
33. Lee TS, Yen HC, Pan CC, Chan LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:734-742.
34. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res. 2002;90:E34-E38.
35. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064-1071.
36. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17-e24.
37. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;19:2847-2853.
38. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003;59:234-240.
39. Hansson GK, Hellstrand M, Rymo L, et al. Interferon gamma inhibits both proliferation and expression of alpha smooth muscle actin in arterial smooth muscle cells. J Exp Med. 1989;170:1595-1608.
40. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1223-1230.
41. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999;274:11924-11929.
42. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002;106:3024-3030.
43. Geng YJ, Wu Q, Muszynski M, et al. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16:19-27.
44. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
45. Mallat Z, Golova A, Brun V, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2003; 108:1232-1237.
46. Robertson AK, Rudling M, Zhou X, et al. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003; 112:1342-1350.
47. Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood. 2003; 102:4052-4058.
48. Kronenberg M, Brossay L, Kurepa Z, Forman J. Conserved lipid and peptide presentation functions of nonclassical class I molecules. Immunol Today. 1999;20:515-521.
49. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
50. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002;109:745-753.
51. Andersen HO, Holm P, Stender S, et al. Dose-dependent suppression of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine. Arterioscler Thromb Vasc Biol. 1997;17:2515-2523.
52. Ruygrok PN, Muller DW, Serruys PW. Rapamycin in cardiovascular medicine. Intern Med J. 2003;33:103-109.
53. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807-818.
54. Jonasson L, Holm J, Hansson GK. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc Natl Acad Sci U S A. 1988;85:2303-2306.
55. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-661.
56. Makheja AN, Bloom S, Muesing R, et al. Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis. 1989;76:155-161.
57. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
58. Steinbrecher U. Oxidation of human low density lipoprotein results in derivatization of the lysine residues of lipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262:3603-3608.
59. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation. 1997; 95:1062-1071.
60. Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11:103-112.
61. Palinsky W, Rosenfeld ME, Ylä-Herttuala, et al. Low density lipoprotein undergoes modification in vivo. Proc Natl Acad Med U S A. 1989;86:1372-1376.
62. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev. 2002; 1:233-237.
63. Maggi E, Marchesi E, Ravetta V, et al. Low-density lipoprotein oxidation in essential hypertension. J Hypertens. 1993;11:1103-1111.
64. Maggi E, Bellazzi R, Gazo A, et al. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int. 1994;46:869-876.
65. Wu R, de Faire U, Lemne C, et al. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999;33:53-59.
66. Lehtimaki T, Lehtinen S, Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19:23-27.
67. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol. 2001;21:269-274.
68. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol. 2001;21:101-107.
69. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002;22:662-666.
70. Tornvall P, Waeg G, Nilsson J, et al. Autoantibodies against modified low-density lipoproteins in coronary artery disease. Atherosclerosis. 2003;167:347-353.
71. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
72. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
73. Ameli S, Hultgårdh-Nilsson A, Regnström J, et al. Effect of immunization with homologous LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074-1079.
74. Freigang S, Horkko S, Miller E, et al. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol. 1998;18:1972-1982.
75. Nilsson J, Calara F, Regnström J, et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon in hypercholesterolemic rabbits. J Am Coll Cardiol. 1997;30:1886-1891.
76. Zhou X, Caligiuri G, Hamsten A, et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21:108-114.
77. Palinski W, Ord VA, Plump AS, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehydelysine in serum. Arterioscler Thromb. 1994; 14:605-616.
78. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in ApoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:872-878.
79. Reyes OS, Chyu KY, Yano J, et al. Immunization with a novel apoB100-related peptide reduces atherosclerosis and inflammation in ApoE null mice. J Am Coll Cardiol. 2002;(39)suppl A.
80. Fredrikson GN, Soderberg I, Lindholm M, et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol. 2003;23:879-884.
81. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:95-100.
82. Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
83. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117-128.
84. Friedman P, Horkko S, Steinberg D, et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J Biol Chem. 2002;277:7010-7020.
85. Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A. 1999;96:6353-6358.
86. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105:1731-1740.
87. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med. 1982; 156:1177-1185.
88. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003;9:736-743.
89. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106-2112.
90. Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169:113-120.
91. Hansen PR, Chew M, Zhou J, et al. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. Atherosclerosis. 2001;158:87-94.
92. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039-3045.
93. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalization for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-1332.
94. Gurfinkel EP, de la Fuente L, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventios: the Flu Vaccination Acute Coronary Syndromes (FLU-VAC) study. Circulation. 2002;105:2143-2147.
95. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease. A new opportunity for prevention and need for further studies. Circulation. 2003;108:2730-2736.
96. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153-264.
97. Faria AM, Maron R, Ficker SM, et al. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun. 2003;20:135-145.
98. Harats D, Yacov N, Gilburd B, et al. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol. 2002;40:1333-1338.
99. Maron R, Sukhova G, Faria AM, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1708-1715.